CHD2 deficiency therapy(Mahzi Therapeutics Inc)

N/A

Report date: 2025/10/20 14:18:45

Base Information

Drug NameCHD2 deficiency therapy(Mahzi Therapeutics Inc)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionChromodomain-helicase-DNA-binding protein 2 stimulants
TargetsChromodomain-helicase-DNA-binding protein 2
Therapy Area/IndicationsRare neurological diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMahzi Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesWeizmann Institute Of ScienceMahzi Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRare neurological diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A